CAS NO: | 2070009-55-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | PF-2771 is a potent and selectivecentromere protein E (CENP-E)inhibitor, inhibiting CENP-E motor activity with anIC50of 16.1 nM; PF-2771 is used as an anticancer agent. | ||||||||||||||||
IC50& TargetHY-19530[1] |
| ||||||||||||||||
体外研究 (In Vitro) | PF-2771 is a potent and selective CENP-E inhibitor, inhibiting CENP-E motor activity with an IC50of 16.1 nM. PF-2771 shows no inhibitory effect on the ATPase activities of highly related kinesins (0% inhibition of Eg5/KSP, chromokinesin, and MCAK at both 1 or 10 μM PF-2771). PF-2771 exhibits inactive activity against 74 protein kinases (all< 23% inhibition with 1 μM PF-2771,< 40% with 10 μM PF-2771). PF-2771 is cytotoxic to the basal-like breast cancer tumor cell survival, with EC50s of< 0.1 μM, and with no cytotoxicity on the normal and premalignant cell lines (EC50>5 μM). PF-2771 (100 nM) reusults in a chromosomal congression defect in MDA-MB-468 cells[1]. | ||||||||||||||||
体内研究 (In Vivo) | PF-2771 (100 mg/kg, every day i.p.) potently inhibits CENP-E motor function, and causes tumor regression in SCID mice bearing AA1077 mammary tumors[1]. | ||||||||||||||||
分子量 | 554.08 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C29H36ClN5O4 | ||||||||||||||||
CAS 号 | 2070009-55-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 32 mg/mL(57.75 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|